<DOC>
	<DOC>NCT01389102</DOC>
	<brief_summary>Estradiol treatment is effective at reducing vasomotor symptoms (eg hot flushes) in postmenopausal women. This study will evaluate the safety and efficacy of Evamist.</brief_summary>
	<brief_title>Estradiol Transdermal Spray in the Treatment of Vasomotor Symptoms</brief_title>
	<detailed_description>Multicenter, randomized, double-blind, placebo-controlled trial evaluating different doses of transdermal estradiol delivered by sray to symptomatic postmenopausal women. The endpoints are the reduction in frequency and severity of hot flushes.</detailed_description>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Post menopausal women, Ages 35 or older, Frequent moderate to severe hot flushes, Qualifying general medical health Disqualifying gynecological disorders, Disqualifying dermatological disorders, Disqualifying concurrent conditions</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Postmenopause</keyword>
	<keyword>Hot Flashes</keyword>
	<keyword>Estradiol</keyword>
	<keyword>Polyestradiol phosphate</keyword>
	<keyword>Estradiol valerate</keyword>
	<keyword>Estradiol 3-benzoate</keyword>
	<keyword>Estradiol 17 beta-cypionate</keyword>
	<keyword>Estrogens</keyword>
	<keyword>Hormones</keyword>
	<keyword>Hormones, Hormone Substitutes</keyword>
	<keyword>Hormone Antagonists</keyword>
</DOC>